Stockwinners Market Radar for December 30, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

16:41 EST Matthews enters into consultation agreement with Barington - Matthews announced that it has entered into an agreement with Barington Capital, Barington Companies Equity Partners, L.P., and Barington Companies Management, pursuant to which Barington Companies Management will serve as a consultant to Matthews. Under the agreement, Barington has also agreed to vote all of its shares in favor of Matthews' nominees at the 2023 Annual Shareholders' Meeting.

16:35 EST SWVL Holdings Corp trading resumes

16:21 EST SM Energy general counsel David Copeland to retire, James Lebeck to succeed - SM Energy announced the retirement of executive VP and general counsel David Copeland. The retirement of Copeland from his current position will be effective December 31 and he will remain with the company in an advisory role until July 1, 2023. The company also announced that James Lebeck will take the position of senior VP and general counsel. Since 2018, Lebeck has served as VP and chief legal officer at Encino Energy.

16:10 EST Realty Income to acquire 185 single-tenant retail and industrial properties - Realty Income Corporation announced that it has signed a definitive agreement to acquire up to 185 single-tenant retail and industrial properties from subsidiaries of CIM Real Estate Finance Trust for approximately $894M in cash. The portfolio composition may vary based upon the completion of our due diligence and the potential exercise of rights of first refusal related to certain properties. The transaction is expected to close in Q1 of 2023, subject to customary closing conditions, approvals and completion of due diligence.

16:01 EST SWVL Holdings Corp trading halted, news pending

13:31 EST LiveOne raises 2023 Audio Division adjusted EBITDA view to $17.5M-$19M - LiveOne is increasing guidance for its Audio Division to $17.5M - $19M in Adjusted EBITDA without corporate overhead expense allocation for its fiscal year ending March 31, 2023. LiveOne's current cash balance is $8.6M and short term assets are $25M. In addition, LiveOne plans to IPO Slacker Radio as a separate public company during its 2024 fiscal year.

13:26 EST Petrobras says price adjustments made in normal course of business - Petrobras, regarding the pieces of news in the media about expectations of new adjustments in fuel prices, clarifies that adjustments in product prices are made in the normal course of its business and follow its current commercial policies. "Petrobras reiterates its commitment to the practice of competitive prices, in balance with the market, while avoiding the immediate pass-through of external volatility and exchange rate volatility caused by circumstantial events. Petrobras continuously monitors the markets, which includes, among other procedures, the daily analysis of the behavior of our prices relative to international quotations," the company said in a regulatory filing.

12:57 EST Brazil's Lula nominates Jean Paul Prates for Petrobras CEO - President-elect of Brazil Luiz Inacio Lula da Silv confirmed via Twitter that Jean Paul Prates has been nominated for the presidency of Petrobras. Prates, according to Bloomberg, has said Petrobras's current management is steering the company "off a cliff" by narrowly focusing on oil and gas and neglecting the energy transition.

12:33 EST ING completes share buyback program, to pay remaining EUR 297M to holders - ING announced that it has completed the share buyback program that started on November 3. The total number of shares repurchased under the program is 107,032,745 ordinary shares at an average price of EUR 11.25 for a total consideration of EUR 1,203,635,570.77. During the last week of the program from December 26 up to and including December 28, ING has repurchased 43 shares. These shares were repurchased at an average price of EUR 11.61 for a total amount of EUR 499.13. In line with the announcement of the program on November 3, the remainder of the total amount of EUR 1.5 billion, amounting to EUR 297M, or EUR 0.082 per share, will be paid to shareholders in cash on January 16, 2023, the company stated.

12:00 EST Atento falls -6.5% - Atento is down -6.5%, or -28c to $4.00.

12:00 EST Waterdrop falls -10.1% - Waterdrop is down -10.1%, or -34c to $3.02.

12:00 EST FiscalNote rises 8.5% - FiscalNote is up 8.5%, or 47c to $6.03.

11:33 EST Kala Pharmaceuticals trading resumes

11:07 EST Gorilla Technology Group Inc trading resumes

10:00 EST LiveWire falls -4.7% - LiveWire is down -4.7%, or -22c to $4.43.

10:00 EST Waterdrop falls -8.0% - Waterdrop is down -8.0%, or -27c to $3.09.

10:00 EST FiscalNote rises 11.5% - FiscalNote is up 11.5%, or 64c to $6.20.

09:58 EST Rogers, Shaw rally after Competition Tribunal approves merger - Shares of Rogers Communications (RCI) and Shaw Communications (SJR) are moving higher after Canada's Competition Tribunal approved the merger between the two companies. The Tribunal determined the proposed transactions and ancillary agreements comprising the arrangement "are not likely to prevent or lessen competition substantially." It added, "In other words, the Merger and Divestiture are not likely to result in materially higher prices, relative to those that would likely prevail in the absence of the arrangement. The Merger and Divestiture are also unlikely to result in materially lower levels of non-price dimensions of competition, relative to those that would likely exist in the absence of the arrangement. Such nonprice dimensions of competition include service, quality, variety, and innovation." Shares of Rogers are up 5% to $47.27 and Shaw is up 10% to $28.98 in early trading following the approval.

09:48 EST Model Performance Acquisition Corp trading halted, volatility trading pause

09:47 EST Direxion Daily Semiconductor Bull 3X Shares falls -5.6% - Direxion Daily Semiconductor Bull 3X Shares is down -5.6%, or -54c to $9.13.

09:47 EST Direxion Daily Semiconductor Bear 3X Shares rises 6.0% - Direxion Daily Semiconductor Bear 3X Shares is up 6.0%, or $2.34 to $41.64.

09:47 EST Shaw Communications rises 10.0% - Shaw Communications is up 10.0%, or $2.64 to $29.03.

09:45 EST Southwest says schedule normal today, sees 'minimal disruptions' - Southwest Airlines said it is operating a normal schedule on Friday, December 30. "We appreciate the dedicated work of the Southwest Team to restore our schedule, and we anticipate minimal disruptions for the weekend. Once again, we value the continued patience and support of our valued Customers, and we apologize for the inconveniences of the past week," the company said in a release on its website.

09:21 EST BeiGene announces CDE acceptance of tislelizumab sBLA - BeiGene announced that the Center for Drug Evaluation, or CDE, of the China National Medical Products Administration, or NMPA, has accepted a supplemental biologics license application, or sBLA, for tislelizumab in patients with first-line unresectable or metastatic hepatocellular carcinoma, or HCC.

09:17 EST Vistagen secures additional patent protection for PH94B - Vistagen announced that the company has taken important strategic steps to secure additional patent protection for its lead product candidate, PH94B, through the recent filing of national applications at the U.S. Patent and Trademark Office, or USPTO, and counterpart patent authorities in major pharmaceutical markets outside the U.S. for the treatment of adjustment disorder, or AjD. These new filings are intended to provide a global exclusivity platform for PH94B in AjD, similar to the Company's patent protection for PH94B for the treatment of social anxiety disorder, and for its other late-clinical stage product candidate, PH10, for the treatment of major depressive disorder.

09:08 EST FDA determines Evaxion Biotech can proceed with Phase 2B trial of EVX-01 - In a regulatory filing yesterday evening, the company stated: "As previously announced on September 21, 2022, Evaxion Biotech A/S (EVAX) reached an important milestone when it enrolled its first patient in Perth, Australia in the Company's global Phase 2b clinical trial of EVX-01, the Company's personalized, peptide-based cancer immunotherapy targeting melanoma, in combination with KEYTRUDA(R) an anti-PD-1 inhibitor developed by Merck &Co (MRK). In November 2022, the Company submitted an Investigational New Drug Application along with a Fast Track designation request to the FDA for the Phase 2b clinical trial of EVX-01 in combination with KEYTRUDA for the treatment of patients with metastatic melanoma. On December 22, 2022, the FDA notified the Company that it had reviewed the Company's IND and determined that the Company may proceed with its Phase 2b trial. The Company anticipates a reply from the FDA on its Fast Track designation submission in the first quarter of 2023. It is anticipated that the trial will be conducted globally at clinical sites across the United States, Europe, and Australia in collaboration with Merck, which is supplying the trial with its PD-1 inhibitor, KEYTRUDA. Patients enrolled in the Phase 2b clinical trial will receive standard of care treatment along with KEYTRUDA in combination with EVX-01, or in the event of progression, another standard of care treatment in combination with EVX-01. The Company is responsible for the conduct of the trial. The Company and Merck will continue to collaborate as the data mature. The Phase 2b clinical trial is a single arm trial evaluating the efficacy and safety of EVX-01 in combination with KEYTRUDA, or pembrolizumab, in adults with unresectable or metastatic melanoma. The trial will evaluate if EVX-01 improves the best overall response in patients with an initial assessment of stable disease or partial response after initiating KEYTRUDA treatment, as compared to historical outcomes with KEYTRUDA(R) alone in metastatic or unresectable melanoma. The Company has received approval of its Clinical Trial Applications for the Phase 2b trial from regulatory authorities in Australia, Italy and France. The Company subsequently informed the French regulators that it currently does not intend to conduct the trial in France. In addition, the Company submitted a CTA in Spain and is awaiting approval by the Spanish regulatory authorities." Shares of Evaxion Biotech are up 22% at $2.16 in pre-market trading.

09:05 EST Dynagas LNG announces time charter contract for Arctic Aurora - Dynagas LNG Partners announced that it has entered into a new time charter party agreement with Equinor for the employment of the 2013 built ice class LNG carrier Arctic Aurora. Under the new time charter agreement, the Arctic Aurora is expected to be delivered to Equinor in September 2023 in direct continuation of the current charter party with Equinor, meaning there will be no lapse of time between the current and the new time charter. The term 'in direct continuation' does not refer to the contracted income. The new time charter period is about 3 years adding about $116.5M to the Partnership's existing contracted revenue backlog.

09:04 EST Digital Brands completes acquisition of Sundry - Digital Brands Group announces that it has completed its previously announced acquisition of Sundry. As a result of the transaction, Sundry has become a wholly owned subsidiary of DBG. "The Sundry acquisition is expected to contribute significant revenue scale and operating leverage," said Hil Davis, Chief Executive Officer of DBG. "We believe adding Sundry to our Bailey Shop, which is our multi-brand e-commerce site will contribute revenue immediately. Additionally, we are also excited about the large opportunity to expand the Sundry brand into other verticals. We believe that the opportunity to cross merchandise Sundry and their customers to our other brands, add additional product categories and leverage synergies to reduce expenses will be accretive."

09:03 EST NWTN Inc. delivers first batch of electric vehicles to client in UAE - NWTN announced that it delivered 20 range-extended electric vehicles, R-EEVs, to M93 CAR RENTAL L.L.C at its newly constructed facility in the Khalifa Economic Zones Abu Dhabi, KEZAD. The delivery kicks off NWTN's plan to provide the UAE market with a range of innovative products and solutions to promote the region's transformation to sustainable energy. The R-EEVs were the perfect choice for M93 CAR RENTAL and are uniquely suited to the UAE market. The vehicle's range-extended technology overcomes the problems of limited charging facilities in the UAE and the long distances often travelled in the country. The 20 R-EEVs were the first batch of vehicles to be delivered to local clients within coming months. Alan Wu, Chairman and CEO of NWTN said at the delivery ceremony: "We are thrilled to see our products and solutions start contributing to the UAE's Zero Emission Initiative. This is the beginning of our long-term commitment to the UAE and the Middle East market. We will continue to promote green mobility lifestyles and bring world leading sustainable technologies to the UAE to help support the country's 'Net-Zero 2050' strategic initiative and energy transformation blueprint."

08:58 EST Frontline says redomiciliation to Cyprus is effective - Frontline refers to its announcement on December 20, 2022 regarding the approval by Frontline's shareholders at the Special General Meeting held on December 20, 2022, to redomicile the Company to the Republic of Cyprus under the name of Frontline. The Registrar of Companies and Official Receiver of the Republic of Cyprus has today issued a temporary redomiciliation certificate, and the Redomiciliation has therefore taken effect. Frontline Ltd. discontinued its existence as Frontline Ltd. as provided under Sections 132G and 132H of the Companies Act 1981 of Bermuda, and, pursuant to Sections 354(B)-(H) of Cap.113 of the statutes of the Republic of Cyprus, continued its existence as Frontline plc. The business, assets and liabilities of Frontline Ltd. and its subsidiaries prior to the Redomiciliation are the same as Frontline plc immediately after the Redomiciliation on a consolidated basis, as well as its fiscal year. In addition, the directors and executive officers of the Frontline plc immediately after the Redomiciliation are the same individuals who were directors and executive officers, respectively, of Frontline Ltd. immediately prior to the Redomiciliation.

08:43 EST Baijiayun Group announces change in Nasdaq ticker symbol - Baijiayun Group announced that it will change its ticker symbol on the Nasdaq Capital Market from "FFHL" to "RTC." Trading under the new ticker symbol will begin at market opening on Friday, December 30, 2022. Baijiayun announced the successful completion of the merger transaction between Baijiayun Limited and Fuwei Films and the appointment of a new board and management team on December 23, 2022. The Transaction was previously announced on July 19, 2022, and subsequently approved by the shareholders of Fuwei Films at an extraordinary general meeting held on September 24, 2022. Gangjiang Li, chairman of the board and chief executive officer of the Company and founder of Baijiayun Limited, commented, "We are very excited to have our Company start trading under the new ticker 'RTC' on the Nasdaq today. With only five years of development, Baijiayun has rapidly grown to become one of the top players in the billion-dollar video cloud industry in China. As an integrated video-centric technology solution provider with advanced self-developed video technologies, Baijiayun will continue to expand our product portfolio spanning over Video SaaS/PaaS, Video Cloud and Software and Video AI and System Solutions with a view to achieving further breakthroughs."

08:35 EST UP Fintech down 31% at $3.27 after CSRC warning on mainland China operations

08:34 EST Futu Holdings down 27% at $43.07 after CSRC warning on mainland China operations

08:26 EST Agora appoints Steve Zhang to board of directors - Agora announced a change in its board of directors. Jenny Hong Wei Lee has tendered her voluntary resignation from Agora's board of directors due to personal reasons. Steve Zhang has been appointed as a director on Agora's board of directors and will serve as a member of the audit committee and compensation committee. Zhang has over 30 years of experience in the global information technology industry and had served in senior executive roles at information technology firms in Asia and the United States.

08:24 EST Micron slides 2% to $49.60 in pre-market after Argus downgrade to Hold

08:10 EST Bloom Energy enters agreement with Unimicron - Bloom Energy has entered into an agreement with Unimicron, a chip substrate and printed circuit board maker, to deploy up to 10MW of fuel cells at Unimicron plants in Taiwan. The installations will begin in 2023 and be completed by 2026. With this, Bloom Energy will have deployed its solid oxide fuel-cell based Energy Server in four Asian countries.

08:06 EST GT Biopharma announces $6.5M registered direct offering - GT Biopharma announced that it has entered into a definitive securities purchase agreement for the purchase and sale of 6,500,000 shares of the Company's common stock and warrants to purchase up to an aggregate of 6,500,000 shares of common stock at a combined purchase price of $1.00 per share of common stock and associated warrant in a registered direct offering. The warrants have an exercise price of $1.00 per share, will be exercisable commencing six months following issuance, and will have a term of exercise equal to five years following the initial exercise date. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The closing of the offering is expected to occur on or about January 4, 2023, subject to the satisfaction of customary closing conditions. The gross proceeds to the Company from this offering are expected to be $6.5M, before deducting the placement agent's fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from this offering for general corporate purposes.

08:04 EST Labrador Gold reviews year of discovery at Kingsway - Labrador Gold shared a year end review of exploration at its 100% owned Kingsway Project. Exploration during 2022 was focussed on the prospective Appleton Fault Zone that trends over a 12km strike length at Kingsway. Discovery highlights of 2022 exploration include: Extended Big Vein discovery to over 520 metres NE-SW strike length; mineralization remains open in both directions; Both the highest-grade intersection of 284.1 g/t Au over 0.58 metres and the longest intersection of 2.02 g/t Au over 32 metres on the property to date were uncovered at Big Vein; Additional high-grade mineralization found in outcrop at Golden Glove where initial drilling during 2022 intersected 6.22 g/t Au over 4m and 20.07 g/t Au over 1m; Made two brand new discoveries of near surface gold mineralization under cover at the Pristine and Midway targets. Initial drilling at Pristine identified a mineralized zone that currently extends over 135 metres as well as a second parallel zone approximately 25m east; Limited drilling at Midway indicates near surface gold disseminated within an altered gabbroic intrusion, a separate mineralization style with significant potential for expansion along strike; Drilled 36,000 metres in 2022 after doubling the size of the planned drill program to 100,000 metres. The company is fully funded for the remaining 37,496 metres of the planned 100,000 metre program with approximately $18 million in cash. Assays are pending for samples from 3,903 metres of core.

08:01 EST Futu Holdings to 'fully cooperate' with CSRC, 'take all necessary measures' - Futu Holdings makes the following announcement: "Futu noted that the China Securities Regulatory Commission posted an announcement on December 30, 2022 relating to the Company's cross-border operations in mainland China. Futu will fully cooperate with the CSRC and take all necessary measures to review its cross-border operations in mainland China and to comply with all applicable rules and regulations. The Company will proactively seek guidance from and cooperate with the CSRC in connection with its efforts to ensure legal compliance of its business activities in mainland China. In the meantime, the Company will continue to provide high-quality services to existing clients in China and further strengthen and expand its international operations."

08:00 EST NaaS Technology appoints Alex Wu as Chief Financial Officer - NaaS Technology announces that the Company has appointed Alex Wu as its Chief Financial Officer, effective January 15, 2023. This appointment concludes the previously announced executive search process undertaken by the Company. Wu has also been appointed the President of the Company and will join its Board of Directors, effective January 15, 2023. Alex Wu has been serving as the Company's interim chief financial officer since October 1, 2022, and previously served as interim chief financial officer of RISE Education Cayman, the predecessor of the Company, from September 2021 to June 2022.

07:35 EST BiondVax CEO says set the stage in 2022 for 'highly successful' 2023 - BiondVax Pharmaceuticals published a letter from its CEO, Amir Reichman, addressing 2022 accomplishments, preclinical trial results of the inhaled COVID-19 NanoAb therapy as well as recent financing activities to support 2023 objectives. The letter reads in part: "Today, I am thrilled to share even more compelling results from the preclinical trial. New data from the same study shows that the inhaled NanoAb eliminated viral loads in the lungs: Hamsters treated with BiondVax's NanoAb had over 30 times lower SARS-COV-2 viral titers in their lungs, six days after infection compared to the placebo group. ..Looking forward to 2023: The collaboration with MPI and UMG has been more successful than we originally contemplated with a number of new potential NanoAb candidates for indications beyond COVID-19 identified well ahead of schedule, in particular, anti-IL-17 NanoAbs for the treatment of psoriasis as well as other disorders. The highly favorable results from our COVID-19 hamster study and the identification of the IL-17 NanoAbs furthered our confidence to move both programs forward aggressively. Rather than slow down progress, in Q4 we determined to raise the capital to fast-track these programs. This was a difficult decision given overall market conditions. After careful consideration and with no certainty that market conditions would soon improve and realizing that delaying financing would impede progress and heighten the risk that funding would be increasingly difficult to obtain, we concluded that now presented the best opportunity to secure capital. With funding in place to continue development, our plans include executing several steps required to bring our inhaled COVID-19 NanoAb therapy into a first-in-human Phase 1/2a clinical trial by the end of 2023. These steps include toxicology studies and GMP manufacturing of the NanoAb. We also intend to exercise our option to obtain an exclusive license at pre-agreed financial terms to anti-IL-17 NanoAbs from our partners in Germany, scale up in-house NanoAb manufacturing, conduct an in vitro proof-of-concept study and potentially also a preclinical trial of the IL-17 NanoAb as a therapy for psoriasis. Bringing innovative pharmaceutical products through manufacturing, clinical trials and regulatory approvals requires substantial resources and entail a high degree of risk. Our biobetter NanoAb approach is specifically designed to mitigate the cost and risk ordinarily incurred in drug development, and we aim to aggressively pursue partnerships with big pharma that can bring in upfront and milestone payments, royalties, and funding for development activities, thereby further reducing our own funding needs and risk. A NanoAb pipeline may provide us with multiple partnering opportunities as well as flexibility in structuring relationships so as to preserve our upside. We also intend to pursue sources of non-dilutive funding, including grants from NGOs and from Israeli and European governmental organizations and have several grant applications in process. Securing meaningful partnerships with large pharma companies requires generating compelling data from pre-clinical and early clinical trials, which is exactly what we intend to pursue with the funds recently raised and with any grant money we are able to secure in the near future. I believe we have set the stage in 2022 for a highly successful 2023."

07:07 EST Parex Resources announces approval of NCIB, Automatic Share Purchase Plan - Parex Resources announced that the Toronto Stock Exchange has approved the Company commencing a normal course issuer bid. Pursuant to the Bid, Parex will purchase for cancellation, from time to time, as it considers advisable, up to a maximum of 10,675,555 common shares of the Company. The Bid will commence on January 4, 2023 and will terminate on January 3, 2024 or such earlier time as the Bid is completed or terminated at the option of Parex. The maximum number of Common Shares to be purchased pursuant to the Bid represents 10% of the public float, as of December 22, 2022. Purchases pursuant to the Bid will be made on the open market through the facilities of the TSX and/or alternative trading systems. The number of Common Shares that can be purchased pursuant to the Bid is subject to a daily maximum of 141,763 Common Shares. The price that Parex will pay for any Common Shares under the Bid will be the prevailing market price on the TSX at the time of such purchase. Common Shares acquired under the Bid will be cancelled. RBC Dominion Securities Inc. has agreed to act on the Company's behalf to make purchases of Common Shares pursuant to the Bid. Parex believes that the Common Shares have been trading in a price range which does not adequately reflect their value in relation to the Company's current operations and its growth prospects, and that, at such times, the purchase of Common Shares for cancellation will increase the proportionate interest of, and be advantageous to, all remaining shareholders. As of the close of business on December 22, 2022, the Company had 109,108,590 Common Shares issued and outstanding and a public float of 106,755,557 Common Shares. Under a previous notice of intention to conduct a normal course issuer bid, the Company sought and received approval of the TSX to purchase 11,820,533 Common Shares for the period from January 4, 2022 to January 3, 2023. From January 4, 2022 to September 30, 2022, the Company purchased 11,820,533 Common Shares on the open market at a weighted-average price of $20.58 per Common Share. Further, the Company has entered into an automatic share purchase plan with RBC Dominion Securities Inc. in order to facilitate repurchases of its Common Shares. Under the Company's automatic share purchase plan, RBC Dominion Securities Inc. may repurchase Common Shares under the Bid during the Company's self-imposed blackout periods. Purchases will be made by RBC Dominion Securities Inc. based upon the parameters prescribed by the TSX and applicable securities laws and the terms of the plan and the parties' written agreement. The automatic share purchase plan has been approved by the Toronto Stock Exchange and will be implemented effective January 4, 2023.

07:06 EST LSB Industries says shutdown facilities to reduce Q4 operating income by $5M-$7M - LSB Industries announced that its Cherokee, Alabama and El Dorado, Arkansas facilities were shut down as a result of the extremely cold temperatures that impacted much of the United States in late December. The El Dorado facility has since returned to service. Repairs are currently underway at Cherokee and the facility is expected to resume production by mid-January 2023. LSB management estimates that the unplanned outages at the two facilities will collectively reduce fourth quarter 2022 operating income by approximately $5M to $7M, largely attributable to lost sales and reduced absorption of fixed costs.

07:04 EST CTO Realty Growth acquires The Collection at Forsyth for $96M - CTO Realty Growth announced it has acquired The Collection at Forsyth, a 560,000 square foot lifestyle, mixed-use property in the Forsyth County submarket of Atlanta, Georgia for a purchase price of $96M. The purchase price represents a going-in cap rate above the range of the Company's current guidance for initial cash yields. The Property is just over 80% leased and serves an expansive trade area with highly desirable demographics, including a 5-mile population over 146,000 people with 5-mile average household incomes of more than $172,000. The Property was purchased using proceeds from the Company's recent equity offering, available unrestricted cash, and draws from the Company's unsecured revolving credit facility. The acquisition was structured as a reverse like-kind exchange in order to account for possible future dispositions of income properties by the Company.

06:39 EST AmerisourceBergen calls DOJ complaint 'an attempt to shift blame' from DEA - AmerisourceBergen issued a response to the Department of Justice complaint filed yesterday, stating in part: "The complaint filed by the Department of Justice attempts to shift the onus of interpreting and enforcing the law from the Department of Justice and Drug Enforcement Administration to an industry they are tasked with regulating and policing. The simple fact is DEA controlled and operated systems like the ability to limit the amount of opioid medication available through manufacturing quotas; and maintenance of registration for pharmacies that dispense controlled substances like opioid medications were not used to stem the crisis of opioid misuse and abuse... In each of these examples - which were cherry picked by DOJ from the thousands of pharmacies AmerisourceBergen delivers medicines to be the most incriminating to the company - the DEA received information directly from AmerisourceBergen on the pharmacy and it's ordering of controlled substances like opioids. And in each case AmerisourceBergen invested time and money to take action before the DEA did. Perhaps the most fundamental demonstration of this fact is that the Department of Justice complaint never accuses AmerisourceBergen of delivering opioid based medicines to a pharmacy that the Department of Justice's own agency - the DEA - had not registered themselves. An objective review of the facts shows that the DOJ's complaint about AmerisourceBergen is simply an attempt to shift blame from past administrations at the Department of Justice and specifically their agency, the DEA, to industries they were tasked with regulating. Congress investigated the DEA's conduct and found that they did not use tools like registration and manufacturing quotas to address opioid abuse and misuse. And recently a Federal Judge in West Virginia noted in a decision for AmerisourceBergen and two of its competitors, that the companies had maintained diversion control systems in accordance with the law. This sweeping decision addressed many of the same accusations that are made in this DOJ complaint and concluded that AmerisourceBergen had complied with the law." Reference Link

06:33 EST Ault Alpha purchases 50M shares of common stock of BitNile - BitNile Holdings announced that its related party, Ault Alpha, has purchased an aggregate of 50M shares of common stock of BitNile since it first started buying in September 2021. Ault Alpha purchases common stock of BitNile pursuant to a plan previously adopted pursuant to Rule 10b5-1 and Rule 10b-18 of the Securities Exchange Act of 1934, as amended. The 50M shares of common stock represent approximately 13% of the Company. "BitNile reported approximately $610M in total assets as of September 30, 2022 and recently completed the acquisition of Circle 8, the crane company. Ault Alpha intends to continue its purchase of common stock of BitNile if the current market conditions continue. Ault Alpha anticipates adopting a new 10b5-1/10b-18 plan in the near future," said Milton Ault, III, the controlling person of Ault Alpha and the Executive Chairman of BitNile.

06:20 EST Ecopetrol announces union files petition on collective bargaining agreement - Ecopetrol informed that the company's coexisting unions filed a petition on the current collective bargaining agreement. Ecopetrol also filed a partial petition before the Ministry of Labor. The company's current collective bargaining agreement, covering Ecopetrol's direct workers, was initially signed in 2018 for a term of four and a half years and is set to expire on December 31. Pursuant to applicable Colombian law, parties to the collective bargaining agreement have the right to express their intent to modify it, by filing a petition to commence negotiations. In the event that the unions present a list of demands, Ecopetrol and the union's leadership will begin the negotiation process for a new collective bargaining agreement.

06:10 EST High Tide to open Canna Cabana store in Etobicoke, Ontario - The Company announced that its Canna Cabana retail cannabis store located at 170 Queen Street North, Etobicoke, Ontario, will begin selling recreational cannabis products and consumption accessories for adult use tomorrow, December 31, 2022. This first Etobicoke store is Canna Cabana's 150th in Canada and the 49th in Ontario.

06:06 EST New York City REIT board approves 1-for-8 reverse stock split - NYC announced that its board approved a 1-for-8 reverse stock split pursuant to which each outstanding share of common stock will be converted into 0.125 shares of common stock. The reverse stock split is expected to be effective at 5:00p.m. eastern time on January 11, 2023. Further, subject to executing necessary documents and board approval, the Company intends to launch a rights offering to raise additional capital from existing stockholders.

06:02 EST Aurora Mobile receives minimum bid price notice from Nasdaq - Aurora Mobile announced that it has received written notification from the staff of the Listing Qualifications Department of The Nasdaq Stock Market dated December 28, 2022, indicating that for the last 32 consecutive business days, the closing bid price for the Company's American depositary shares was below the minimum bid price of $1.00 per share requirement set forth in Nasdaq Listing Rule 5450(a)(1). The Nasdaq notification letter has no current effect on the listing or trading of the Company's ADSs on Nasdaq. Pursuant to the Nasdaq Listing Rule 5810(c)(3)(A), the Company is provided with a compliance period of 180 calendar days, or until June 26, 2023, to regain compliance under the Nasdaq Listing Rules. If at any time during the 180-day compliance period, the closing bid price of the Company's ADSs is $1.00 per share or higher for a minimum of ten consecutive business days, Nasdaq will provide the Company written confirmation of compliance and the matter will be closed. In the event the Company does not regain compliance by June 26, 2023, subject to the determination by the staff of Nasdaq, the Company may be eligible for an additional 180-day compliance period. The Nasdaq notification letter does not affect the Company's business operations, and the Company will take all reasonable measures to regain compliance within the prescribed compliance period.

05:36 EST WISeKey CEO issues letter to shareholders - WISeKey released a letter to shareholders from Carlos Moreira, WISeKey's Founder and CEO. The letter said, "As the year comes to a close, we want to take this opportunity to summarize our significant business milestones, as well as provide some insight into the strategic direction of WISeKey for 2023 and beyond. While 2022 was a challenging year for everyone, with the COVID-19 pandemic affecting communities and businesses around the world, I am proud to say that despite these challenges, due to the resilience and adaptability of our team and our business, we were able to end the year with record revenues. For fiscal 2022 revenue we expect to report revenue of over $24.5 million, an increase of more than 10% compared to FY 2021, due to steady semiconductors demand and an ambitious roadmap to develop the next generation of post-quantum chips. We have worked hard to navigate the uncertain and rapidly changing environment, and we are pleased to report that WISeKey has remained financially strong during 2022. The divestiture of arago GmbH had a positive impact on our liquidity, as it reduced cash burn by approximately 40% and allowed us to focus on revenue generating investments. During the year, we continued to make progress on our strategic initiatives and invest in our future growth. It is likely that technology foundations of WISeKey will continue to advance and play a significant role in many aspects of daily life in 2023. Some areas that may see significant developments in the next few years including AI, virtual and augmented reality, IoT, NFTs, quantum and cybersecurity. There may also be continued progress in fields such as robotics and space low orbit satellites. WISeKey is well positioned to take advantage of the growing demand for these technologies. It is important to note that technology can have both positive and negative impacts on society, and it is essential to consider the ethical implications of new developments as they arise, which is the foundation of our Company's mission statement. As you are aware, we have seen significant volatility in the global stock markets which has caused concern for many investors. It's important to keep in mind that short-term market movements are not necessarily indicative of long-term trends and that it is normal for the stock market to experience ups and downs. WISeKey's stock price has also seen the effect of market volatility. While analysts covering our stock have a target price well above our current trading price, we believe that our stock price doesn't reflect the real value of our business and growth opportunities ahead of us, but we also understand that market fluctuations and other global macro-economic developments remain outside of our control. We encourage our shareholders to stay informed about the progress of WISeKey and reach out to their financial advisor. Moving forward, we expect our total revenue to continue to grow in 2023, driven by a projected revenue growth for the IoT segment of at least 40%. We believe that due to our large backlog of $36 million, which we expect to deliver within the next 48 months, our $100 million pipeline of opportunities, and the significant investments we have made into expanding our salesforce, we are well positioned to continue to gain market share and expand our geographic footprint. I want to take this opportunity to express my gratitude to our shareholders, business partners, clients and also our wonderful team of employees around the globe for the continued support you have shown us over the years. We remain committed to delivering long-term value. On behalf of our management team and board of directors, I wish you and your loved ones a happy and healthy 2023."

05:11 EST Borr Drilling awarded new contracts for two jack-up drilling rigs - Borr Drilling announced it has been awarded new contracts for two of its premium jack-up drilling rigs. These awards increase the company's backlog by approximately 2,030 days, excluding optional periods. The premium jack-up drilling rig "Frigg" has secured long-term contract from an undisclosed customer for work in the Middle East. This contract has a firm duration of five years plus options and is expected to commence in the third quarter of 2023 following the completion of the rig's reactivation. The estimated contract value of the firm term, including mobilization fee, is $282M. The premium jack-up drilling rig "Gunnlod" has received a binding letter of award from an undisclosed customer for work in Southeast Asia. The program has an estimated duration of 205 days and is expected to commence in June 2023 following the completion of its current firm contracts and a statutory periodic survey. The estimated contract value is $27.5M. These awards increase the company's contracted fleet to 21 rigs out of a total of 22 delivered rigs.